Howard W. Levine Esq.

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Levine, Howard W.

Howard W. Levine is a Partner in the Washington, D.C., office of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, where his practice concentrates on patent litigation before the federal district courts and the U.S. Court of Appeals for the Federal Circuit, primarily in the areas of biotechnology and pharmaceuticals. Mr. Levine has extensive experience in cases arising from the filing of Abbreviated New Drug Applications (ANDA).

Over the last 20 years, Mr. Levine has represented both pharmaceutical and biotechnology companies in technologies ranging from the inhibition of NF-κB to genetically engineered corn. Mr. Levine was involved in litigations between Eli Lilly, Genentech, and the Regents of the University of California regarding human insulin, the first biotechnology product to be marketed. Some of the products involved in the litigations Mr. Levine served as counsel include Humulin®, Humatrope®, Zantac®, Paxil®, Evista®, Xigris®, Cymbalta®, Gemzar®, and Differin®.

Mr. Levine has conducted all aspects of pre-trial, trial, and post-trial proceedings, including appeals to the Federal Circuit and the U.S. Supreme Court. Mr. Levine lectures on the subject matter of patent law, including such topics as the written description and the patentability of different crystalline forms of drug substances.

Mr. Levine received his B.A. from Duke University and his J.D. from Georgetown University.

He is the co-author of the 2013 supplement to the Bloomberg BNA treatise Biotechnology and the Federal Circuit.